Trial of a new drug in KRAS-mutant lung cancer
A new study has just been launched that will study a new drug, VIC-1911, alone or given in combination with Lumakras (sotorasib) for patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC), according to VITRAC Therapeutics, the maker of VIC-1911. VIC-1911 works by inhibiting the amplification or overexpression of the AURKA gene, which previous research …
